AlzeCure Pharma to Present Update on Phase II Neuropathic Pain Candidate ACD440
核心洞察
AlzeCure Pharma (搜索) will host a live event on October 23rd to discuss their Phase II candidate ACD440 for chronic neuropathic pain (搜索).
The symposium will feature an overview of pain management by Dr. Rolf Karlsten and an update on ACD440 by CMO Märta Segerdahl.
ACD440, a topical TRPV1 (搜索) antagonist, showed positive proof-of-mechanism results, reducing pain induced by cold and heat by approximately 50% in trials.
AlzeCure Pharma (搜索) AB is set to host a live event on October 23rd, focusing on their Phase II clinical candidate, ACD440, a novel topical treatment for chronic neuropathic pain (搜索). The symposium, titled "ACD440 - A novel non-opioid analgesic", will feature Dr. Rolf Karlsten, alongside AlzeCure's CMO and project manager, Märta Segerdahl, providing an in-depth look at the drug's development and the broader landscape of pain management.
ACD440: A Novel Approach to Neuropathic Pain
ACD440 is a first-in-class TRPV1 (搜索) antagonist administered topically for peripheral neuropathic pain (搜索). Originating from Big Pharma through strategic in-licensing, the drug candidate boasts a strong scientific foundation, with its underlying research having been awarded a Nobel Prize in 2021. The topical gel formulation is designed to minimize systemic exposure while maintaining a high local concentration of the substance, maximizing analgesic effects over extended periods.
Positive Proof-of-Mechanism Results
In 2023, AlzeCure reported positive proof-of-mechanism (PoM) results from a Phase II study of ACD440 in patients with chronic peripheral neuropathic pain (搜索). The study demonstrated that ACD440 had a significant analgesic effect, reducing pain induced by cold and heat by approximately 50%. This reduction is considered clinically relevant, addressing temperature hypersensitivity, a common and debilitating issue for individuals with neuropathic pain. These results aligned with previously reported Phase I findings, further supporting the drug's potential.
Well-Tolerated Topical Treatment
The Phase II study also highlighted that ACD440, when applied topically as a gel, was well-tolerated by patients. The substance and its administration route demonstrate good suitability for further clinical development, suggesting a promising future for ACD440 as a non-opioid treatment option for neuropathic pain (搜索).
Addressing a Significant Unmet Need
Neuropathic pain (搜索) affects an estimated 7-8% of the global adult population, with conditions like diabetes and HIV increasing the risk. Current treatments often fail to provide adequate relief, with 70-80% of patients not achieving effective pain management. The need for new, non-opioid treatments is critical, given the risks associated with opioid use. AlzeCure's development of ACD440 represents a significant step towards addressing this unmet medical need.